Conferences - Results from #9400

ESMO 2017: SPAZO2 (SOGUG): Validation of the International Metastatic Database Consortium prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib in metastatic renal cell carcinoma September 13, 2017

ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide September 13, 2017

ESMO 2017: Cabazitaxel followed by ADT improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A Randomized, Open Label, Phase III, Multicenter trial September 13, 2017

ESMO 2017: Assessment of health-related quality of life in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 vs 25 mg/m2 in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) September 13, 2017

ESMO 2017: Outcomes of patients with metastatic renal cell carcinoma who were treated with second-line vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line immune checkpoint inhibitor therapy September 13, 2017

ESMO 2017: Association between biopsychosocial distress and overall survival in patients with metastatic renal cell carcinoma September 13, 2017

ESMO 2017: SPAZO2 (SOGUG): Comparative effectiveness of everolimus vs axitinib as second-line after first-line pazopanib in metastatic renal carcinoma September 12, 2017

ESMO 2017: Do patients with advanced nonseminomatous germ cell tumors and unfavorable time to normalization of tumor markers benefit with prolongation of 1-st line chemotherapy? September 12, 2017

ESMO 2017: Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma: A retrospective study September 12, 2017

ESMO 2017: Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) September 12, 2017

ESMO 2017: Medical Costs and Health Care Resource Use in Elderly US Patients With Newly Diagnosed Metastatic or Surgically Unresectable Urothelial Carcinoma Using Surveillance, Epidemiology, and End Results (SEER) Medicare Data September 12, 2017

ESMO 2017: Real World Treatment Costs and Resource Utilization among Patients with Metastatic Bladder Cancer September 12, 2017

ESMO 2017: The prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic germ cell tumors September 12, 2017

ESMO 2017: Management of M0 Patient with Rising PSA: How can PET imaging help? September 12, 2017

ESMO 2017: The M0 Patient with Rising PSA - Case Presentation: The clinical problem, a multi-disciplinary issue September 12, 2017

ESMO 2017: A Phase II Clinical Trial of Radium-223 Activity in Patients with mCRPC with Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status (EXCAAPE) September 11, 2017

ESMO 2017: Immune Checkpoint Inhibitors in Prostate Cancer September 11, 2017

ESMO 2017: Comparison of tumor mutational burden in relevant molecular subsets of metastatic urothelial cancer September 11, 2017

ESMO 2017: Therapeutic Vaccines in Prostate Cancer September 11, 2017

ESMO 2017: Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial September 11, 2017

Page 471 of 616